New milestone achieved presented during the EASD annual congress!

Resukts EASD

The results of our new cross-sectional study conducted in France on T2D patients demonstrated the ability of our behavioral diagnostic tool SPUR™ to measure medication non-adherence. 
These results are comparable to the findings from our previous cross-sectional study surveying T2D patients in the UK, confirming SPUR™ as a new validated measure of medication non-adherence across countries for this pathology. The UK results have been published in "The International Journal of Pharmacy Practice" and were presented at the Health Services Research and Pharmacy Practice (HSRPP) online conference. 
SPUR™ demonstrates very promising results and has the potential to become THE new standard in adherence measurement. 
Additional studies are currently underway in other countries and diseases to complement these data. 

Read more about SPUR™ scientific communications

If you want to discover more in details our complete SPUR™ Research Plan, we invite you to download our infographics. 

Download the SPUR™ Research Plan full infographic


We are processing this data per your request only. We are hosting the data internally. We will not share it.

This data will be used to send you the requested content and other types of content on related topics and will be kept for a maximum of 3 years.

Here’s a link to our privacy policy. You can find out how to send a request to access your data, request to delete your data, correct any inaccuracies or restrict our processing of your data.

You have the right to lodge a complaint about the way we handle your data with French Data Protection authority CNIL or you can contact our DPO at contact form for more information or with concerns.


See also

Scientific communications

A multiple-cohort analysis of the SPUR 6/24 patient-reported adherence tool


Clinical Ink and Observia: Pioneering Personalized Patient Engagement in Clinical Trials


By your side in 2024: Happy Holidays from Observia!

Accès plateformes